Exelixis Escapes Cancer Drug Invalidity Bid At PTAB

Exelixis has beaten back a challenge to one of its patents covering the blockbuster drug Cabometyx after the Patent Trial and Appeal Board denied Azurity Pharmaceuticals' request to review the patent....

Already a subscriber? Click here to view full article